Loading stock data…
CNSP
$4.51-0.08 (-1.74%)
Market OpenUpdated 2:52 PM EDT
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
CNS Pharmaceuticals, Inc. in the Healthcare sector is trading at $4.51 with a market capitalization of $8M. Wall Street consensus targets $10.00 (1 analysts), implying a +121.7% move over the next 12 months. The stock is currently 64% below its 52-week high of $12.36, remaining 20.2% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +121.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$4.98M↑ | -$5.99M↓ | -$3.25M↓ | -$2.41M↑ | -$4.34M |
| Net Income | -$4.94M↑ | -$5.96M↓ | -$3.22M↓ | -$2.37M↑ | -$4.30M |
Peer Comparison
JNJUNHPFE
Fundamentals
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$7.66M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.54
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-23317.01%
Volume
Today's trading volume
28,597
Recent News
Forget the 242% Biotech Meme. This Brain Cancer Stock Has a $38 Analyst Target and Trades at $6
CNS Pharmaceuticals (NASDAQ:CNSP) is back on every biotech watchlist after a 242.36% one-week ramp tied to its Berubicin glioblastoma story. But here’s what you should actually be watching. Holders captured the move; new entrants face tougher math from here. The market cap sits at roughly $6.36 million, the company reported a Q1 2024 net loss ... Forget the 242% Biotech Meme. This Brain Cancer Stock Has a $38 Analyst Target and Trades at $6
Top Midday Gainers
Celcuity (CELC) reported late Friday positive topline results from a cohort of its phase 3 Viktoria-
CNS Pharmaceuticals upgraded to Buy at Maxim on TPI-287 roadmap
As previously reported, Maxim upgraded CNS Pharmaceuticals (CNSP) to Buy from Hold with a $20 price target The company has pivoted to its oncology asset TPI-287, a blood brain barrier crossing taxane in development initially for recurrent glioblastoma, the analyst tells investors in a research note. Maxim further cites CNS Pharma’s road map for TPI-287, as well as a potential path forward with Berubicin and cash runway into the second half of 2026, as positioning the stock toward a recovery. Pub